(HHT) |
| 0 (0%) 08-28 05:41 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 40.14 |
| Resistance 1: | 39.37 |
| Pivot price: | 38.95 |
| Support 1: | 38.12 |
| Support 2: | 31.72 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 2.690 |
| Book Value | 37.120 |
| PEG Ratio | 0.61 |
| Gross Profit | 22.168 |
| Profit Margin (%) | 12.73 |
| Operating Margin (%) | 15.80 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 7.6 |
Company news
Wed, 26 Aug 2026
ABC-Channel 7 News: "Catching HHT Early Could Save Your Life" Sky Vs Valkyries (ajUWFXvAGM) - Mshale
Thu, 20 Aug 2026
Cure HHT Announces Palmer Family Fund Travel Award Recipients for 16th HHT International Scientific Conference - EIN News
Wed, 12 Aug 2026
Swiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3 - European Biotechnology Magazine
Tue, 11 Aug 2026
Vaderis raises $152M Series B for late-stage HHT drug trial - Dealroom
Tue, 11 Aug 2026
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia - PR Newswire
Tue, 11 Aug 2026
Vaderis hauls in $152M to test an AKT-targeting drug - BioPharma Dive
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
